Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Resistance to Immunotherapeutic Antibodies in Cancer

Strategies to Overcome Resistance - Previously published in hardcover
BuchKartoniert, Paperback
202 Seiten
Englisch
Springererschienen am22.08.2015Softcover reprint of the original 1st ed. 2013
The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.mehr
Verfügbare Formate
BuchKartoniert, Paperback
EUR160,49
BuchGebunden
EUR160,49

Produkt

KlappentextThe book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
ZusammenfassungThis book examines antibody-mediated anti-cancer therapy, covering the use of mAbs against various cancers, developments in the molecular, biochemical and genetic mechanisms of resistance by various mAbs and novel mAbs to overcome drug and radition resistance.
Details
ISBN/GTIN978-1-4899-8732-7
ProduktartBuch
EinbandartKartoniert, Paperback
Verlag
Erscheinungsjahr2015
Erscheinungsdatum22.08.2015
AuflageSoftcover reprint of the original 1st ed. 2013
ReiheResistance to Targeted Anti-Cancer Therapeutics
Seiten202 Seiten
SpracheEnglisch
Gewicht338 g
IllustrationenXIII, 202 p.
Artikel-Nr.35523045
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
Preface.- Introduction and generation of chimeric and humanized mAbs.- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment.- Antibodies directed against different major cancers: Effects when used  alone or in combination with drugs.- Mechanisms of antibodies-mediated responses, in vitro and in vivo.- Molecular Pathways.- Molecular Signatures.- Identification of resistance targets for intervention.- Various chemicals that can sensitize resistant tumor cells.- Other mAbs.- Proteasome inhibitors.- Divalent mAbs.- Antibodies coupled to chemical inhibitors.- Antibodies coupled to cytokines.- Nanoparticles with mAbs.- Index.mehr

Autor

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.